Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/metabolism; Pyrimidines/pharmacokinetics; Pyrimidines/therapeutic use; Thiazoles/pharmacokinetics; Thiazoles/therapeutic use; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1/antagonists & inhibitors; ATP Binding Cassette Transporter, Subfamily B, Member 1/physiology; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters/physiology; Animals; Antineoplastic Agents/pharmacokinetics; Antineoplastic Agents/therapeutic use; Benzamides; Biological Transport/drug effects; Dasatinib; Drug Evaluation, Preclinical; Fusion Proteins, bcr-abl/metabolism; HL-60 Cells; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood; Mice; Neoplasm Proteins/physiology; Organic Cation Transporter 1/genetics; Organic Cation Transporter 1/metabolism; Piperazines/pharmacokinetics; Temperature; Tumor Cells, Cultured